Review Papers Claim by Claim

1) What the paper does well

• Comprehensive, readable narrative bringing together mechanisms (e.g., mTOR, AMPK, Wnt, STAT3, PAK1, COX) and preclinical/clinical evidence for each candidate drug Antoszczak et al., review summary
• Provides pharmacokinetic and toxicity notes for each drug class (helps translational thinking)
• Highlights translational paths (sensitizers, CSC targeting, chemoprevention) rather than only single-agent claims

2) Primary limitations and blindspots

1. Narrative (non‑systematic) review: selection strategy is not reproducible — risk of selection/publication bias and overweighting positive preclinical results. The authors acknowledge this limitation in places but do not present a systematic search or PRISMA flow to quantify omitted/negative studies Narrative review method note
2. Heterogeneous evidence: drugs range from agents with randomized RCT signals (aspirin chemoprevention meta-analyses) to single small phase I trials (artesunate) or mainly in vitro data (ivermectin), so recommendations should be drug‑specific, not uniform.
3. Translational gap underemphasized: PK/PD differences — e.g., ivermectin tissue distribution, artesunate short half‑life, doxycycline dosing vs anti‑CSC effect — require explicit human dose‑mapping and safety-first trial designs; the review lists PK facts but stops short of formal human exposure vs in vitro EC50 comparisons that would flag infeasible repurposing opportunities PK discussion in review
4. Safety/iatrogenic risk balance: many agents have known serious toxicities in oncologic settings (thalidomide neuropathy/thrombosis; rapamycin immunosuppression/dyslipidemia; aspirin bleeding). The review mentions toxicity but readers need a tabulated risk-benefit frame per indication.

3) Evidence grading — practical reading of the review

If you read the review to prioritize a candidate for an early clinical trial in cancer, weigh:

• Strength of human data: metformin (epidemiology + randomized small trials), aspirin (epidemiology and RCT meta-analyses), rapamycin analogues (approved oncology indications) — highest translational priority.
• Promising preclinical mechanistic depth but sparse human data: artesunate, doxycycline, ivermectin — preclinical→phase I bridging required (PK/PD + toxicity profiling).
• Well‑established repurposing success case: thalidomide → multiple myeloma (demonstrates feasibility but also safety caveats).

4) Concrete next steps (for researchers/funders)

1. Systematic re-review and meta‑analysis for each candidate drug (preclinical EC50/IC50 distribution, in vivo exposures, human PK Cmax) to identify which agents reach achievable tumor exposures — priority: artesunate, doxycycline, ivermectin mapping required.
2. Design PK/PD bridging studies: single‑agent phase I cohorts with tumor biopsies and plasma PK + pharmacodynamic readouts (apoptosis markers, γ-H2AX, RAD51 etc.).
3. Use organoid/xenograft matched models (PDOs) to test clinically achievable drug concentrations and rational combinations suggested by review (e.g., artesunate + oxaliplatin; rapamycin + metformin) before trials Combination signals in review
4. Prioritize randomized, biomarker‑driven phase II trials for agents with epidemiologic support (aspirin, metformin) but design them to collect mechanistic biomarkers and adjudicate harms (e.g., bleeding, lactic acidosis).